Cited by 318Liver Disease Diagnosis and TreatmentLiver Diseases and ImmunityLiver physiology and pathology

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial†

Leuschner, Ulrich F. H., Lindenthal, Birgit, Herrmann, Günter, Arnold, Joachim C., Rössle, Martin, Cordes, Hans‐Jörg, Zeuzem, Stefan, Hein, Jasper, Berg, Thomas·2010·Hepatology

DOI 10.1002/hep.23727

Open this paper in CoChat — free account

Abstract

UNLABELLED: In uncontrolled clinical studies, ursodeoxycholic acid (UDCA) had a beneficial effect on nonalcoholic steatohepatitis (NASH). However, a large controlled trial using UDCA (13-15 mg/kg/day) was unable to confirm these results. Accordingly, a randomized, placebo-controlled study was initiated with a high dose of UDCA (23-28 mg/kg/day). The allocation of patients and the evaluation of liver histology were performed according to a modified Brunt score and the nonalcoholic fatty liver disease activity score (NAS). With the modified Brunt score, 185 patients with histologically proven NASH were randomized [intention to treat (ITT)], and 147 were treated per protocol (PP). With the NAS, 137 patients were confirmed to have NASH, 48 had borderline NASH, and 1 did not have NASH. The treatment time was 18 months. At entry, the treatment groups were comparable. A second biopsy sample was obtained from 139 of 185 patients (NAS: 107/137). The primary criterion for evaluation was a change in the liver histology; the secondary criteria were single histological variables and liver biochemistry. Significant differences in the overall histology could not be detected between the two treatment groups with the modified Brunt score (P = 0.881) or NAS (P = 0.355). Only lobular inflammation improved significantly (P for the modified Brunt score = 0.011, P for NAS = 0.005). In subgroup analyses, significant improvements in lobular inflammation were also observed in males, younger patients up to 50 years of age, slightly overweight patients, and patients with hypertension and an increased histology score. The fibrosis score did not change (P for ITT = 0.133, P for PP = 0.140). With the exception of gamma-glutamyl transferase, UDCA did not improve laboratory data. CONCLUSION: High-dose UDCA failed to improve the overall histology in patients with NASH in comparison with placebo.

Integrity signals

Registry

Crossref · 10.1002/hep.23727

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,728
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma
Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., CARUCCI, P., Musso, A., Paolis, P. D., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,436
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392

Flagged first, then by citations

Show all 36 references

Research works printed but not linked: 1

Padda, 1999, The effect of ursodeoxycholic acid (UDCA) treatment on liver tests in patients with non alcohol induced steatohepatitis (NASH), Am J Gastroenterol, 94, A334

Sorted by citations

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,854
AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,805
Dietary lipids, gut microbiota and lipid metabolism
Schoeler, M., & Caesar, R. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09512-0 · Cited by 1,163
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2016) · Diabetologia · doi:10.1007/s00125-016-3902-y · Cited by 695
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
Musso, G., Cassader, M., Rosina, F., & Gambino, R. (2012) · Diabetologia · doi:10.1007/s00125-011-2446-4 · Cited by 661
Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M., & Trauner, M. (2017) · Hepatology · doi:10.1002/hep.28709 · Cited by 634
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · The American Journal of Gastroenterology · doi:10.1038/ajg.2012.128 · Cited by 594
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
European Association for the Study of the Liver (EASL), E. A. F. T. S. O. D. (. (2016) · Obesity Facts · doi:10.1159/000443344 · Cited by 531
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Fuchs, C. D., & Trauner, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00566-7 · Cited by 490
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH)
Takaki, A., Kawai, D., & Yamamoto, K. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141020704 · Cited by 460
NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications
Farrell, G. C., Rooyen, D. M. V., Gan, L. T., & Chitturi, S. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.2.149 · Cited by 408
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
Ratziu, V., de Ledinghen, V., Oberti, F., Mathurin, P., Wartelle-Bladou, C., Renou, C., Sogni, P., Maynard, M., Larrey, D., Serfaty, L., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.030 · Cited by 338
Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk
Muzurović, E. M., Mikhailidis, D. P., & Mantzoros, C. S. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154770 · Cited by 363
Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis
Kuang, J., Wang, J., Li, Y., Li, M., Zhao, M., Ge, K., Zheng, D., Cheung, K. C.-P., Liao, B., Wang, S., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.011 · Cited by 330
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Watanabe, S., Hashimoto, E., Ikejima, K., Uto, H., Ono, M., Sumida, Y., Seike, M., Takei, Y., Takehara, T., Tokushige, K., et al. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1050-7 · Cited by 328
Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment
Smith, B. W., & Adams, L. A. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.72 · Cited by 334
The role of oxidative stress in non-alcoholic steatohepatitis
Koek, G. H., Liedorp, P. R., & Bast, A. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.04.013 · Cited by 315
Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
Mueller, M., Thorell, A., Claudel, T., Jha, P., Köfeler, H. C., Lackner, C., Hoesel, B., Fauler, G., Stojaković, T., Einarsson, C., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.034 · Cited by 327
Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children
Kleiner, D. E., & Makhlouf, H. R. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.011 · Cited by 303
Non-alcoholic fatty liver disease
Smith, B. W., & Adams, L. A. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.596521 · Cited by 300
A concise review of non-alcoholic fatty liver disease
Than, N. N., & Newsome, P. N. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.001 · Cited by 296
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals
Masuoka, H. C., & Chalasani, N. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12016 · Cited by 290
Involvement of free radicals and oxidative stress in NAFLD/NASH
Sumida, Y., Niki, E., Naito, Y., & Yoshikawa, T. (2013) · Free Radical Research · doi:10.3109/10715762.2013.837577 · Cited by 280
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
Tokushige, K., Ikejima, K., Ono, M., Eguchi, Y., Kamada, Y., Itoh, Y., Akuta, N., Yoneda, M., Iwasa, M., Yoneda, M., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01796-x · Cited by 282
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Kang, S. H., Lee, H. W., Yoo, J., Cho, Y., Kim, S. U., Lee, T. H., Jang, B. K., Ahn, S. B., Ahn, S. B., Kim, H., et al. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0178 · Cited by 276
Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease
Torres, D. M., Williams, C. D., & Harrison, S. A. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.03.011 · Cited by 275
Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo
Williams, K., Shackel, N. A., Gorrell, M. D., McLennan, S. V., & Twigg, S. M. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1009 · Cited by 235
Review article: is non‐alcoholic fatty liver disease a spectrum, or are steatosis and non‐alcoholic steatohepatitis distinct conditions?
Yilmaz, Y. N. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12046 · Cited by 217
Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives
Hu, H., Lin, A., Kong, M., Yao, X., Yin, M., Xia, H., Ma, J., & Liu, H. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01649-8 · Cited by 211
Prevalence and risk factors for non‐alcoholic fatty liver disease in Asian people who are not obese
Liu, C. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2012.07222.x · Cited by 209
Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications
Roma, M. G., Toledo, F. D., Boaglio, A. C., Basiglio, C. L., Crocenzi, F. A., & Pozzi, E. J. S. (2011) · Clinical Science · doi:10.1042/cs20110184 · Cited by 207
Non-alcoholic fatty liver disease: What the clinician needs to know
Machado, M. V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i36.12956 · Cited by 215
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Watanabe, S., Hashimoto, E., Ikejima, K., Uto, H., Ono, M., Sumida, Y., Seike, M., Takei, Y., Takehara, T., Tokushige, K., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12511 · Cited by 197
Non-alcoholic Fatty Liver Disease and Metabolic Syndrome—Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology
Duseja, A. K., Singh, S. P., Saraswat, V. A., Acharya, S. K., Chawla, Y. K., Chowdhury, S., Dhiman, R. K., Jayakumar, R. V., Madan, K., Misra, S. P., et al. (2015) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2015.02.006 · Cited by 193
Pathogenesis of NASH: how metabolic complications of overnutrition favour lipotoxicity and pro-inflammatory fatty liver disease
Farrell, G. C., Haczeyni, F., & Chitturi, S. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-8684-7_3 · Cited by 178
Non-alcoholic fatty liver disease in 2015
Ahmed∥, M. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i11.1450 · Cited by 186
Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Takahashi, Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i13.3777 · Cited by 162
Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground
Chitturi, S., Wong, V. W., & Farrell, G. C. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06548.x · Cited by 163
Revision and update on clinical practice guideline for liver cirrhosis
Suk, K. T., Baik, S. K., Yoon, J., Cheong, J. Y., Paik, Y. H., Lee, C. H., Kim, Y. S., Lee, J. W., Kim, D. J., Cho, S. W., et al. (2012) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2012.18.1.1 · Cited by 142
Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version
Лазебник, Л. Б., Голованова, Е. В., Туркина, С. В., Raikhelson, K. L., Okovityy, S. V., Drapkina, O. M., Maev, I. V., Ai, M., Ройтберг, Г. Е., Khlynova, O. V., et al. (2021) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-185-1-4-52 · Cited by 165
The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease
Song, M. J., & Malhi, H. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107401 · Cited by 146
The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Chow, M. D., Lee, Y., & Guo, G. L. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.04.004 · Cited by 143
Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
Tokushige, K., Ikejima, K., Ono, M., Eguchi, Y., Kamada, Y., Itoh, Y., Akuta, N., Yoneda, M., Iwasa, M., Yoneda, M., et al. (2021) · Hepatology Research · doi:10.1111/hepr.13688 · Cited by 148
The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review
Xiang, Z., Chen, Y., Ma, H., Ye, Y.-F., Zheng, L., Yang, Y., Li, Y., & Jin, X. (2013) · BMC Gastroenterology · doi:10.1186/1471-230x-13-140 · Cited by 143
Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis
Han, M. A. T., Altayar, O., Hamdeh, S., Takyar, V. K., Rotman, Y., Etzion, O., Lefebvre, E. A., Safadi, R., Ratziu, V., Prokop, L. J., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.06.011 · Cited by 135
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
Harrison, S. A., Gunn, N., Neff, G. W., Kohli, A., Liu, L., Flyer, A., Goldkind, L., & Bisceglie, A. M. D. (2021) · Nature Communications · doi:10.1038/s41467-021-25701-5 · Cited by 137
Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
Kim, H.-M., Lee, D. S., An, T. H., Park, H., Kim, W. K., Bae, K., & Oh, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094495 · Cited by 133
Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)
Takaki, A., Kawai, D., & Yamamoto, K. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15057352 · Cited by 127
Non-alcoholic fatty liver disease and diabetes: From physiopathological interplay to diagnosis and treatment
Leite, N. C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8377 · Cited by 125
Nonalcoholic fatty liver disease and cardiovascular disease
Liu, H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8407 · Cited by 118
Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
Jiao, T., Ma, Y., Guo, X., Ye, Y., & Xie, C. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00880-z · Cited by 122
Treatment efficacy of a probiotic preparation for non‐alcoholic steatohepatitis: A pilot trial
Манжалій, Е., Virchenko, O., Falalyeyeva, T. M., Beregova, T. V., & Stremmel, W. (2017) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12561 · Cited by 118
Molecular Mechanisms of Ursodeoxycholic Acid Toxicity & Side Effects: Ursodeoxycholic Acid Freezes Regeneration & Induces Hibernation Mode
Kotb, M. A. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13078882 · Cited by 117
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
(2013) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2013.19.4.325 · Cited by 115
Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota
Doulberis, M., Kotronis, G., Gialamprinou, D., Kountouras, J., & Katsinelos, P. (2017) · Metabolism · doi:10.1016/j.metabol.2017.03.013 · Cited by 117
Nonalcoholic fatty liver disease: Update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine
Noureddin, M., Mato, J. M., & Lu, S. C.-L. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215579161 · Cited by 116
Dietary bile acids regulate the hepatic lipid homeostasis in tiger puffer fed normal or high-lipid diets
Liao, Z., Sun, B., Zhang, Q., Jia, L., Wei, Y., Liang, M., & Xu, H. (2020) · Aquaculture · doi:10.1016/j.aquaculture.2020.734935 · Cited by 106
Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma
Lau, H. C.-H., Zhang, X., & Yu, J. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01089-1 · Cited by 126
Current therapeutic strategies in non‐alcoholic fatty liver disease
Dowman, J. K., Armstrong, M. J., Tomlinson, J., & Newsome, P. N. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01403.x · Cited by 100
Endocrine causes of nonalcoholic fatty liver disease
Marino, L. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i39.11053 · Cited by 93
Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets
Younossi, Z. M., Reyes, M. J., Mishra, A., Mehta, R., & Henry, L. L. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12543 · Cited by 93
Mechanisms Linking Nonalcoholic Fatty Liver Disease with Coronary Artery Disease
Nseir, W., Shalata, A., Marmor, A. T., & Assy, N. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1767-y · Cited by 93
A Current Understanding of Bile Acids in Chronic Liver Disease
Farooqui, N., Elhence, A., & Shalimar, S. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.08.017 · Cited by 94
Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options
Milić, S., Mikolašević, I., Zrnić, I. K., Stanić, M., Poropat, G., Štimac, D., Vlahović-Palčevski, V., & Orlić, L. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s64877 · Cited by 97
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
Traussnigg, S., Schattenberg, J. M., Demir, M., Wiegand, J., Geier, A., Teuber, G., Hofmann, W. P., Kremer, A. E., Spreda, F., Kluwe, J., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30184-0 · Cited by 88
Self-citation
Ursodeoxycholic acid accelerates bile acid enterohepatic circulation
Zhang, Y., Jiang, R., Zheng, X., Lei, S., Huang, F., Xie, G., Kwee, S. A., Yu, H., Farrar, C. E., Sun, B., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14705 · Cited by 88
Nonalcoholic Fatty Liver Disease, Diabetes Mellitus and Cardiovascular Disease: Newer Data
Mavrogiannaki, A. N., & Migdalis, I. N. (2013) · International Journal of Endocrinology · doi:10.1155/2013/450639 · Cited by 87
Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction
Kim, D. J., Yoon, S., Ji, S. C., Yang, J., Kim, Y., Lee, S., Yu, K., Jang, I., Chung, J., & Cho, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-30349-1 · Cited by 93
Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease
Pathil, A., Mueller, J., Warth, A., Chamulitrat, W., & Stremmel, W. (2011) · Hepatology · doi:10.1002/hep.25531 · Cited by 81
Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities
Radun, R., & Trauner, M. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1731707 · Cited by 83
Specific bile acids inhibit hepatic fatty acid uptake in mice
Nie, B., Park, H. M., Kazantzis, M., Lin, M., Henkin, A. H., Ng, S. M., Song, S., Chen, Y., Tran, H., Lai, R., et al. (2012) · Hepatology · doi:10.1002/hep.25797 · Cited by 79
Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease
Nadinskaia, M. Y., Maevskaya, M. V., Ivashkin, V. T., Kodzoeva, K. B., Пирогова, И. Ю., Ev, C., Vitalevich, N. A., Kaibullayeva, J. A., Konysbekova, A., Raissova, A., et al. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i10.959 · Cited by 78
The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans
Ballestri, S., Nascimbeni, F., Romagnoli, D., Baldelli, E., & Lonardo, A. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0306-9 · Cited by 79
Postbiotic Impact on Host Metabolism and Immunity Provides Therapeutic Potential in Metabolic Disease
Fang, H., Lacerda, R. R. E., Barra, N. G., Zada, D. K., Robin, N., Mehra, A., & Schertzer, J. D. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae025 · Cited by 82
Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease
Yoon, H. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i11.800 · Cited by 75
A critical review of endpoints for non-cirrhotic NASH therapeutic trials
Ratziu, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.12.001 · Cited by 74
Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD)
Lombardi, R., Onali, S., Thorburn, D., Davidson, B. R., Gurusamy, K. S., & Tsochatzis, E. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011640.pub2 · Cited by 74
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
Lee, B., Lee, Y., Park, C., Rhee, E., Lee, W., Kim, N. H., Choi, K. M., Park, K., Choi, Y., Soo, B., et al. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0010 · Cited by 79
Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model
Li, H., Wang, Q., Chen, P., Zhou, C., Zhang, X., & Chen, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.788558 · Cited by 73
Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Dong, Y., Lv, Q., Li, S., Wu, Y., Li, L., Li, J., Zhang, F., Sun, X., & Tong, N. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.11.009 · Cited by 71
Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ A randomized open‐label controlled study
Kim, M. Y., Cho, M.-Y., Baik, S. K., Jeong, P. H., Suk, K. T., Jang, Y. O., Yea, C. J., Kim, J. W., Kim, H. S., Kwon, S. O., et al. (2012) · Liver International · doi:10.1111/j.1478-3231.2012.02774.x · Cited by 71
Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult
Paul, J. (2020) · Egyptian Liver Journal · doi:10.1186/s43066-020-00043-x · Cited by 73
Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions
Gerges, S. H., Wahdan, S. A., Elsherbiny, D. A., & El‐Demerdash, E. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119220 · Cited by 76
Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis
Ng, C. H., Xiao, J., Lim, W. H., Chin, Y. H., Yong, J. N., Tan, D. J. H., Tay, P., Syn, N., Foo, R., Chan, M., et al. (2022) · Hepatology · doi:10.1002/hep.32315 · Cited by 69
Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: Long-term results
Pietu, F. J., Guillaud, O., Walter, T., Vallin, M., Hervieu, V., Scoazec, J., & Dumortier, J. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.10.011 · Cited by 70
Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH
Carino, A., Biagioli, M., Marchianò, S., Fiorucci, C., Zampella, A., Monti, M. C., Scarpelli, P. T., Ricci, P., Distrutti, E., & Fiorucci, S. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.07.006 · Cited by 70
Nonalcoholic Fatty Liver Disease
Paredes, A. H., Torres, D. M., & Harrison, S. A. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.03.005 · Cited by 72
A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD
Hossain, N., Kanwar, P., & Mohanty, S. R. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/7109270 · Cited by 70
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis
Mahjoubin‐Tehran, M., Vincentis, A. D., Mikhailidis, D. P., Atkin, S. L., Mantzoros, C. S., Jamialahmadi, T., & Sahebkar, A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101049 · Cited by 70
Current Treatment Options for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Beaton, M. D. (2012) · Canadian Journal of Gastroenterology · doi:10.1155/2012/725468 · Cited by 70
Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review
Arab, J. P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.12182 · Cited by 66
Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis
Lambrecht, J., van Grunsven, L. A., & Tacke, F. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1774553 · Cited by 64

Authors: Leuschner, U. F. H., Lindenthal, B., Herrmann, G., Arnold, J. C., Rössle, M., Cordes, H., Zeuzem, S., Hein, J., & Berg, T.
Affiliations: Krankenhaus Sachsenhausen (DE)
Goethe University Frankfurt (DE)
Klinikum Ludwigsburg (DE)
Agaplesion Diakonieklinikum Rotenburg (DE)
University Hospital Leipzig (DE)
Corresponding author: Leuschner, Ulrich F. H.
ORCID: Zeuzem, Stefan
Berg, Thomas
Venue: Hepatology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2010-08
Volume: 52
Issue: 2
Pages: 472-479
ISSN: 0270-9139 (ISSN-L)
DOI: 10.1002/hep.23727
OpenAlex: W2097677758
Cited by: 317
References: 36
Citations by year: 2026: 9 · 2025: 7 · 2024: 13 · 2023: 14 · 2022: 15 · 2021: 29 · 2020: 17 · 2019: 25 · 2018: 15 · 2017: 21 · 2016: 20 · 2015: 25 · 2014: 23 · 2013: 25 · 2012: 25
FWCI: 19.31
Type: journal article
Language: en
Open access: closed
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1857 d)
Locations: Hepatology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: ursodeoxycholic acid, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, liver histopathology, lobular inflammation, liver fibrosis, liver biochemistry, gamma-glutamyl transferase
MeSH terms: Adolescent, Adult, Aged, Double-Blind Method, Fatty Liver, Female, Humans, Male, Middle Aged, Ursodeoxycholic Acid, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial†

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks